AusBiotech has extended its alliance with MTPConnect, the Growth Centre for Australia’s medical technology, biotechnology and pharmaceutical sector, by signing a new Memorandum of Understanding (MoU) to collaborate.
MTPConnect CEO Dr Dan Grant joined AusBiotech CEO Lorraine Chiroiu at the AusBiotech 2018 national conference in Brisbane last week to sign the MoU.
Dr Grant says the agreement creates more opportunities for collaboration for organisations in Australia and international companies investing in Australia.
“AusBiotech has been significant in opening the doors for Australian life science companies to engage with Asian markets and promote the sector,” Dr Grant said.
“In March, we had Australian companies pitch their world-leading health innovations to more than 70 Asian investors at AusBiotech’s Asian Investment Series.
“The agreement will see our two organisations working together to continue providing in-market support and introductions to potential investors and customers, exchanging information on key issues and trends, supporting inbound and outbound missions and the delivery of joint projects.”
AusBiotech CEO Lorraine Chiroiu says she’s delighted to be able to continue working with MTPConnect to enhance Australian life sciences sector.
“Our cooperation agreement with MTPConnect creates unique collaboration and access opportunities for Australia’s healthtech startups, SMEs and researchers,” Ms Chiroiu said.
“The work we did together for the Asian Investment Series is a good example of what can be achieved through collaboration in Asia and the MoU with MTPConnect provides a mechanism to turn those opportunities into reality.
“With a renewed agreement in place with MTPConnect, we’ll be able to continue our collaborations with them to drive innovations which will ultimately improve patient outcomes.”